News

Blood vessel inflammation caused by ANCA antibodies should be considered in the differential diagnosis of familial Mediterranean fever with hyperthyroidism, a case study shows. The study, “Antineutrophil cytoplasmic antibody-positive familial Mediterranean fever and hyperthyroidism: A case report,” was published in the journal Medicine. Familial Mediterranean…

Researchers reported for the first time the case of a patient with ANCA-associated vasculitis whose condition caused bleeding in the brain and spinal cord, most likely because of a ruptured aneurysm. The study, “Anti-neutrophil cytoplasmic antibody associated central nervous system vasculitis with brain and spinal cord subarachnoid…

Omalizumab, an injectable medication approved for allergic asthma, might reduce asthma symptoms and steroid dosages in patients with eosinophilic granulomatosis with polyangiitis (EGPA), according to a retrospective study. The study, “Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) single-center experience in 18 cases,” was published in …

Early identification of granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) overlap is critical for prognosis, long-term treatment, and management of these two distinct diseases, a case report shows. Although few instances of this rare event have been reported, clinicians should be aware of this possibility…

Patients with ANCA-associated vasculitis (AAV) carrying specific variants of the glucocorticoid receptor (GR) gene NR3C1 have a greater risk of death and of developing end-stage renal disease, according to a large study. Also, patients with a variant of the gene coding for an enzyme that regulates glucocorticoids —…

InflaRx will soon launch a Phase 2 clinical trial in Europe to assess the safety and effectiveness of IFX-1 — an investigational inhibitor of the complement system — in patients with ANCA-associated vasculitis (AAV). Now that European authorities have approved it, the randomized, placebo-controlled Phase 2 trial is expected to recruit approximately…

Azathioprine an oral immunosuppressant used as a maintenance therapy for ANCA-associated vasculitis (AAV) patients — may in rare cases cause a hypersensitive reaction of tender, red bumps on the skin, called Sweet’s syndrome, a case report shows. The report, “Sweet syndrome: a rare feature of ANCA-associated vasculitis or unusual…

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Hydralazine, a medication commonly used to lower blood pressure, may in rare cases cause ANCA-associated vasculitis (AAV), a new case report shows. The study, “Hydralazine-induced MPO-ANCA Renal-Limited Vasculitis Masquerading as Lupus Nephritis,” was published in the Journal of the…

Elevated levels of the CD64 protein on the surface of neutrophils – a type of immune cell – accurately distinguishes bacterial infection from disease flares in patients with ANCA-associated vasculitis (AAV) and systemic lupus erythematosus (SLE), a study has found. The study, “Utility of neutrophil…